Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Parkinson’s disease (PD) market is expected to see significant growth in the 7MM*, with the decade starting 2019 seeing an impressive 12.6% compound annual growth rate (CAGR), according to GlobalData. The leading data and analytics company notes that this growth is largely driven by the launch of 17 new pipeline products, which are set to address key unmet needs in the space. However, these will come at a higher cost compared to the currently marketed products, fueling market growth. The market is expected to rise from $3.5bn in 2019 to $11.5bn in 2029.

Sarah Elsayed, Neurology Analyst at GlobalData, comments: “The PD market is highly competitive, featuring many levodopa-combination therapies and adjunctive drug classes that aim to alleviate motor symptoms. However, these current treatment options are primarily symptomatic, off-patent, and not very effective in controlling the motor fluctuations that occur in advanced-stage patients.

“As a result, there are key unmet needs for drugs that have improved efficacy and delivery systems, and that provide disease-modifying benefits. New pipeline agents will aim to address some of these unmet needs and will have higher costs compared to the marketed products, which will fuel the growth of the PD market.”

Leading development strategies in PD across the pipeline mainly include the development of novel targets with potential disease-modifying properties and drug reformulations with innovative delivery systems.

Elsayed continues: “GlobalData anticipates that the most promising pipeline product will be Roche/Prothena’s PRX-002 (prasinezumab), an anti-alpha synuclein monoclonal antibody (mAb) in Phase II development. This drug has shown to potentially halt disease progression in clinical trials. GlobalData forecasts that it will generate global sales of $2.1bn by 2029, achieving the blockbuster status by 2028.”

Several late-stage pipeline agents have innovative systems for delivering levodopa therapy. This includes Intec’s Accordion Pill (levodopa/carbidopa) and Amneal’s IPX203 (levodopa/carbidopa), which are delivered orally in a gastric-retentive capsule to prolong the absorption of levodopa. Conversely, AbbVie’s ABBV-951 (foslevodopa) and Mitsubishi’s ND-0612 (levodopa/carbidopa) are delivered subcutaneously using an external small pump that maintains a continuous and steady flow of levodopa throughout the day and night.

Elsayed adds: “These products are expected to create improved options for physicians to control complications that arise with the continued use of levodopa. Therefore, some of these products are set to gain strong market uptake. The most promising drug in this group is forecast to be AbbVie’s ABBV-951 with global sales of $673.8m by 2029.”

* 7MM: The US, France, Germany, Spain, Italy, the UK, and Japan.


  • Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2019 to 2029.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase IIb and Phase III development are profiled.
  • Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Questions Answered

  • What are the key PD treatments in 2019?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Key Highlights

Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.

GlobalData’s anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.

Roche/Prothena’s, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.

The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.

Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Acorda Therapeutics
Voyager Therapeutics
Amneal Pharmaceuticals
Orion Pharmaceuticals
Intec Pharma
Adamas Therapeutics
Pharma Two B
Britannia Pharmaceuticals
Anavex Life Sciences
Novo Nordisk
Seelos Therapeutics
Living Cell Technologies
Eli Lilly
US WorldMeds
Meiji Seika
Neurocrine Biosciences
Otsuka Pharmaceutical
Kyowa Kirin
B&A Therapeutics

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Parkinson’s Disease: Executive Summary

1.1 Parkinson’s Market Expected to Grow Significantly, Driven by New Launches

1.2 High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market

1.3 Diverse Pipeline Agents Will Partially Address Key Unmet Needs

1.4 The Entry of Novel Biologics and Innovative Delivery Systems Will Shape the PD Market

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Mechanisms of Cell Death

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for PD (2019-2029)

4.5.1 Diagnosed Prevalent Cases of PD

4.5.2 Sex-Specific Diagnosed Prevalent Cases of PD

4.5.3 Age-Specific Diagnosed Prevalent Cases of PD

4.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging

4.5.5 Diagnosed Prevalent Cases of PD by Type

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Effective Treatment of Motor Complications – Dyskinesia, Off-Episodes, Gait, and Balance Problems

7.3 New Therapies for Non-motor Complications – Psychosis and Dementia

7.4 Neuroprotective/Disease-Modifying Agents

7.5 Improved Drug Formulations

8 R&D Strategies

8.1 Overview

8.1.1 Development of Novel Targets ─ mAbs Targeting α-synuclein, and Gene Therapies

8.1.2 Innovative Drug Delivery Systems

8.1.3 Secondary Indications and Drug Repurposing

8.1.4 Clinical Trial Design

8.1.5 Reliable Biomarkers of Disease Progression

8.1.6 Genetic Studies Required to Learn About Genetic Subtypes of PD

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Managing Epidemiologist

13.6.6 Global Director of Therapy Analysis and Epidemiology

13.6.7 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us


Table 1: Parkinson’s Disease: Key Metrics in the 7MM

Table 2: Modified HY Scale of PD Symptoms

Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2008

Table 4: Risk Factors and Comorbidities of PD

Table 5: Treatment Guidelines for PD

Table 6: Parkinson’s Disease Market – Global Drivers and Barriers, 2019-2029

Table 7: Key Events Impacting Sales for Parkinson’s Disease in the US, 2019-2029

Table 8: Parkinson’s Disease Market – Drivers and Barriers in the US, 2019-2029

Table 9: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2019-2029

Table 10: Parkinson’s Disease Market – Drivers and Barriers in the 5EU, 2019-2029

Table 11: Key Events Impacting Sales for PD in Japan, 2019-2029

Table 12: PD Market – Drivers and Barriers in Japan, 2019-2029

Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country


Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 4: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019

Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD

Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging

Figure 7: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019

Figure 8: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019

Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019

Figure 10: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019

Figure 11: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019

Figure 12: Treatment Algorithm for Parkinson’s Patients

Figure 13: Unmet Needs and Opportunities in PD

Figure 14: Pharmacokinetics of Levodopa

Figure 15: Overview of the Development Pipeline in Parkinson’s Disease

Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period

Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 18: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Sinemet

Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Requip

Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Nuplazid

Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Azilect

Figure 22: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period (2019-2029)

Figure 23: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029

Figure 24: Sales Forecast by Class for Parkinson’s Disease in the US in 2019 and 2029

Figure 25: Sales Forecast by Class for Parkinson’s Disease in the 5EU in 2019 and 2029

Figure 26: Sales Forecast by Class for PD in Japan in 2019 and 2029

Frequently asked questions

Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2029 standard reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2029 in real time.

  • Access a live Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.